MCID: PRC016
MIFTS: 63

Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pre-Eclampsia

MalaCards integrated aliases for Pre-Eclampsia:

Name: Pre-Eclampsia 12 25 44 15 72
Preeclampsia 12 75 25 59 29 55 6 17
Hypertension, Pregnancy-Induced, Susceptibility to 29 6
Pregnancy Associated Hypertension 12 72
Gestational Hypertension 12 15
Proteinuric Hypertension of Pregnancy 12
Gestational Proteinuric Hypertension 25
Transient Hypertension of Pregnancy 72
Hypertension Induced by Pregnancy 12
Preeclampsia, Susceptibility to 6
Pregnancy-Induced Hypertension 25
Pre-Eclamptic Toxaemia 12
Preeclampsia/eclampsia 12
Toxaemia of Pregnancy 12
Toxemia of Pregnancy 25
Pregnancy Toxemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10591
MeSH 44 D011225
ICD10 via Orphanet 34 O14.0 O14.1 O14.2 more
UMLS via Orphanet 73 C0032914
Orphanet 59 ORPHA275555
UMLS 72 C0032914 C0341934 C0852036

Summaries for Pre-Eclampsia

Genetics Home Reference : 25 Preeclampsia is a complication of pregnancy in which affected women develop high blood pressure (hypertension); they can also have abnormally high levels of protein in their urine (proteinuria). This condition usually occurs in the last few months of pregnancy and often requires early delivery of the infant. However, this condition can also appear shortly after giving birth (postpartum preeclampsia). Many women with mild preeclampsia do not feel ill, and the condition is often first detected through blood pressure and urine testing in their doctor's office. In addition to hypertension and proteinuria, signs and symptoms of preeclampsia can include excessive swelling (edema) of the face or hands and a weight gain of more than 3 to 5 pounds in a week due to fluid retention. Affected women may also experience headaches, dizziness, irritability, shortness of breath, a decrease in urination, upper abdominal pain, and nausea or vomiting. Vision changes may develop, including flashing lights or spots, increased sensitivity to light (photophobia), blurry vision, or temporary blindness. In many cases, symptoms of preeclampsia go away within a few days after the baby is born. In severe cases, however, preeclampsia can damage the mother's organs, such as the heart, liver, and kidneys, and can lead to life-threatening complications. Extremely high blood pressure in the mother can cause bleeding in the brain (hemorrhagic stroke). The effects of high blood pressure on the brain (hypertensive encephalopathy) may also result in seizures. If seizures occur, the condition is considered to have worsened to eclampsia, which can result in coma. About 1 in 200 women with untreated preeclampsia develop eclampsia. Eclampsia can also develop without any obvious signs of preeclampsia. Between 10 and 20 percent of women with severe preeclampsia develop another potentially life-threatening complication called HELLP syndrome. HELLP stands for hemolysis (premature red blood cell breakdown), elevated liver enzyme levels, and low platelets (cell fragments involved in blood clotting), which are the key features of this condition. Severe preeclampsia can also affect the fetus, with impairment of blood and oxygen flow leading to growth problems or stillbirth. Infants delivered early due to preeclampsia may have complications associated with prematurity, such as breathing problems caused by underdeveloped lungs. Women who have had preeclampsia have approximately twice the lifetime risk of heart disease and stroke than do women in the general population. Researchers suggest that preeclampsia, heart disease, and stroke may share common risk factors. Women who have health conditions such as obesity, hypertension, heart disease, diabetes, or kidney disease before they become pregnant have an increased risk of developing preeclampsia. Preeclampsia is most likely to occur in a woman's first pregnancy, although it can occur in subsequent pregnancies, particularly in women with other health conditions.

MalaCards based summary : Pre-Eclampsia, also known as preeclampsia, is related to mild pre-eclampsia and eclampsia, and has symptoms including edema, hyperemesis gravidarum and morning sickness. An important gene associated with Pre-Eclampsia is NSD1 (Nuclear Receptor Binding SET Domain Protein 1), and among its related pathways/superpathways are Signaling events mediated by VEGFR1 and VEGFR2 and Angiogenesis (CST). The drugs Magnesium oxide and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and liver.

Disease Ontology : 12 A hypertension occurring during pregnancy characterized by large amounts of protein in the urine (proteinuria) and edema, usually by the last trimester of pregnancy.

Wikipedia : 75 Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and... more...

Related Diseases for Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 732)
# Related Disease Score Top Affiliating Genes
1 mild pre-eclampsia 35.8 PGF FLT1
2 eclampsia 35.1 TAC3 STOX1 PGF PEE1 FLT1 ENG
3 hellp syndrome 34.3 PGF FLT1 ENG
4 preeclampsia/eclampsia 1 34.1 PEE1 NSD1
5 placental abruption 32.8 PGF FLT1 ENG
6 microvascular complications of diabetes 5 31.4 PGF NOS3 FLT1
7 arteries, anomalies of 31.4 PGF NOS3 FLT1
8 twin-to-twin transfusion syndrome 31.3 PGF FLT1 ENG
9 atherosclerosis susceptibility 30.9 TUG1 NOS3 H19
10 placenta accreta 30.9 PGF FLT1
11 coronary heart disease 1 30.8 WFDC21P NOS3 H19
12 renal cell carcinoma, nonpapillary 29.6 TUG1 MALAT1 HOTAIR H19 FLT1
13 osteogenic sarcoma 29.3 TUG1 MALAT1 HOTAIR H19
14 lung cancer susceptibility 3 29.0 TUG1 MALAT1 HOTAIR H19
15 pancreatic cancer 28.1 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
16 severe pre-eclampsia 13.2
17 preeclampsia/eclampsia 3 12.4
18 preeclampsia/eclampsia 4 12.3
19 preeclampsia/eclampsia 5 12.3
20 gestational diabetes 11.8
21 trichothiodystrophy 1, photosensitive 11.5
22 alpha-thalassemia 11.5
23 factor v leiden thrombophilia 11.2
24 glomeruloid hemangioma 11.0 FLT1 ENG
25 epithelioid hemangioendothelioma 10.9 PGF FLT1
26 cancer-associated retinopathy 10.8 PGF FLT1
27 placenta disease 10.7
28 hypertension, essential 10.7
29 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.6
30 disseminated intravascular coagulation 10.6
31 thrombocytopenia 10.6
32 yemenite deaf-blind hypopigmentation syndrome 10.6
33 thrombophilia 10.6
34 placental insufficiency 10.6
35 body mass index quantitative trait locus 1 10.6
36 antiphospholipid syndrome 10.5
37 gastric cardia adenocarcinoma 10.5 HOTAIR H19
38 kidney disease 10.5
39 pulmonary edema 10.5
40 vascular disease 10.5
41 acute kidney failure 10.5
42 retinal detachment 10.5
43 chronic kidney disease 10.5
44 autoimmune disease 10.5
45 hydrops, lactic acidosis, and sideroblastic anemia 10.5
46 cortical blindness 10.5
47 hypothyroidism 10.5
48 nephrotic syndrome 10.4
49 encephalopathy 10.4
50 postpartum psychosis 10.4

Graphical network of the top 20 diseases related to Pre-Eclampsia:



Diseases related to Pre-Eclampsia

Symptoms & Phenotypes for Pre-Eclampsia

UMLS symptoms related to Pre-Eclampsia:


edema, hyperemesis gravidarum, morning sickness

Drugs & Therapeutics for Pre-Eclampsia

Drugs for Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 446)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium oxide Approved Phase 4 1309-48-4 14792
2
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Captopril Approved Phase 4 62571-86-2 44093
5
Dalteparin Approved Phase 4 9005-49-6
6
Enoxaparin Approved Phase 4 9005-49-6 772
7
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
8
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Halofantrine Approved Phase 4 69756-53-2 37393
13
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
16
Labetalol Approved Phase 4 36894-69-6 3869
17
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
18
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432 71715
19
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Azithromycin Approved Phase 4 83905-01-5 447043 55185
22
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
23
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
24
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
25
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Desogestrel Approved Phase 4 54024-22-5 40973
29
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
30
Acetaminophen Approved Phase 4 103-90-2 1983
31
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
32
Misoprostol Approved Phase 4 59122-46-2 5282381
33
Metformin Approved Phase 4 657-24-9 4091 14219
34
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
35
Zinc Approved, Investigational Phase 4 7440-66-6 32051
36
Caffeine Approved Phase 4 58-08-2 2519
37
Ethanol Approved Phase 4 64-17-5 702
38
Glyburide Approved Phase 4 10238-21-8 3488
39
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
40
Ibuprofen Approved Phase 4 15687-27-1 3672
41 Garlic Approved, Nutraceutical Phase 4
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
43 Tocotrienol Investigational Phase 4 6829-55-6
44 Tocotrienols Phase 4
45 Tocopherols Phase 4
46 Adrenergic Agonists Phase 4
47 Adrenergic alpha-Agonists Phase 4
48 Central Nervous System Depressants Phase 4
49 Anesthetics Phase 4
50 Anti-Arrhythmia Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 844)
# Name Status NCT ID Phase Drugs
1 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
2 Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial) Unknown status NCT00117546 Phase 4 alpha methyldopa
3 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
4 Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy Unknown status NCT03237000 Phase 4 MgSO4
5 Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages Unknown status NCT01718340 Phase 4 Metformin
6 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
7 Improvement of Utero-Placental Perfusion and Fetal Growth in IUGR and PET by Administration of Sildenafil Citrate in Pregnancy Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
8 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
9 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
10 Study the Effect of Intravenous Hyoscine Butylbromide Injection on the Duration and Progress of First Stage Labour in High Risk Women Unknown status NCT03055390 Phase 4 hyoscine butylbromide;placebo
11 A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
12 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
13 Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients Completed NCT03506724 Phase 4 Nifedipine;Labetalol
14 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
15 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
16 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
17 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
18 Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
19 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
20 Efficacy and Safety of Hyoscine N Butyl Bromide on the Augmentation of Labor: a Double-Blind, Placebo - Controlled Trial Completed NCT02098889 Phase 4 hyoscine-N-butyl bromide(HBB);Saline
21 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
22 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
23 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
24 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
25 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
26 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
27 Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation Completed NCT02353806 Phase 4 Amlodipine besylate
28 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
29 The Comparison of Hyperbaric Bupivacaine Plus Fentanyl and Hyperbaric Levobupivacaine Plus Fentanyl Administered Intrathecally in Patients Undergoing Elective Cesarean Section Completed NCT02025374 Phase 4 Hyperbaric levobupivacaine;Hyperbaric bupivacaine % 0.5
30 A Prospective Multi-centre Randomised Comparison on Induction of Labour With Double-balloon Installation Device Versus Prostaglandin E2 Minprostin Completed NCT01255839 Phase 4 Minprostin
31 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
32 Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia Completed NCT02447250 Phase 4 Varied albuterol dose response
33 Effect of Myofascial Release on Electrophysiological and Clinical Measures of Pregnant Women With Carpal Tunnel Syndrome Completed NCT03802448 Phase 4
34 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
35 Outcomes of Epidural Versus Combined Spinal and Epidural (CSE) Anesthetic Technique on the Success of Trial of Labor After Cesarean (TOLAC): A Pilot Study Completed NCT02105558 Phase 4 Epidural anesthesia;Combined spinal and epidural anesthesia
36 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
37 Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
38 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Recruiting NCT03164304 Phase 4 Magnesium Sulfate
39 Effect of Non-steroidal Anti-inflammatory Use on Blood Pressure in Women With Hypertensive Disorders of Pregnancy: A Randomized Open Label Trial Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
40 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
41 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Recruiting NCT03449277 Phase 4 Oral Tablet
42 Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Recruiting NCT03595982 Phase 4 Procardia XL 30Mg;Procardia XL 60Mg
43 Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial Recruiting NCT04051567 Phase 4 Aspirin 100mg
44 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
45 Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia Recruiting NCT02025426 Phase 4 Phenylephrine;Ephedrine
46 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Recruiting NCT03233880 Phase 4 Azithromycin 1gm
47 Acute Control of Chronic Hypertension in Preeclampsia Recruiting NCT03877692 Phase 4 Experimental dosing of labetalol
48 Acute Labetalol Use in Preeclampsia Randomized Trial Recruiting NCT03872336 Phase 4 Experimental labetalol dose
49 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Recruiting NCT03570632 Phase 4 Metformin
50 Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S. Recruiting NCT02277067 Phase 4 Carbetocin;Misoprostol

Search NIH Clinical Center for Pre-Eclampsia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylsalicylic acid
Hydrochlorothiazide
Magnesium Sulfate

Cochrane evidence based reviews: pre-eclampsia

Genetic Tests for Pre-Eclampsia

Genetic tests related to Pre-Eclampsia:

# Genetic test Affiliating Genes
1 Preeclampsia 29 NOS3
2 Hypertension, Pregnancy-Induced, Susceptibility to 29

Anatomical Context for Pre-Eclampsia

MalaCards organs/tissues related to Pre-Eclampsia:

41
Placenta, Endothelial, Liver, Testes, Kidney, Heart, Lung

Publications for Pre-Eclampsia

Articles related to Pre-Eclampsia:

(show top 50) (show all 28747)
# Title Authors PMID Year
1
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 9 38 71
16059745 2005
2
The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption. 9 38 71
11354626 2001
3
Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. 38 71
11745998 2001
4
Angiotensinogen: a candidate gene involved in preeclampsia? 38 71
8348146 1993
5
A molecular variant of angiotensinogen associated with preeclampsia. 38 71
8513325 1993
6
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 71
17165044 2007
7
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 71
16813604 2006
8
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 71
15007011 2004
9
Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. 71
11394896 2001
10
NOS3 polymorphism not associated with Alzheimer's disease in Japanese. 71
11026457 2000
11
Association between Alzheimer's disease and the NOS3 gene. 71
10514107 1999
12
A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. 71
10510054 1999
13
The Glu-298-->Asp (894G-->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. 71
10475066 1999
14
Coronary artery disease is not associated with the E298-->D variant of the constitutive, endothelial nitric oxide synthase gene. 71
9894802 1998
15
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population. 71
9831339 1998
16
A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. 71
9737779 1998
17
Angiotensinogen gene and hypertension in Chinese. 71
9421481 1998
18
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 71
9259580 1997
19
Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. 71
7649545 1995
20
The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. 71
7883995 1995
21
Rapid detection of the hypertension-associated Met235-->Thr allele of the human angiotensinogen gene. 71
8518804 1993
22
Soluble endoglin in preeclamptic patients with or without HELLP syndrome. 9 38
20430360 2010
23
Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. 9 38
20374043 2010
24
Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. 9 38
20502295 2010
25
The association between preeclampsia and placental disruption induced by chorionic villous sampling. 9 38
20509159 2010
26
Circulating angiogenic factors and their association with birth outcomes in preeclampsia. 9 38
20224572 2010
27
Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. 9 38
19916874 2010
28
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. 9 38
20205159 2010
29
Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. 9 38
20237132 2010
30
Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. 9 38
19269632 2010
31
Nicotine suppresses interleukin-6 production from vascular endothelial cells: a possible therapeutic role of nicotine for preeclampsia. 9 38
20220107 2010
32
Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. 9 38
20206155 2010
33
High levels of human chorionic gonadotropin (hCG) correlate with increased aquaporin-9 (AQP9) expression in explants from human preeclamptic placenta. 9 38
20220109 2010
34
Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. 9 38
20131286 2010
35
Relation between first trimester maternal serum leptin levels and body mass index in normotensive and pre-eclamptic pregnancies--role of leptin as a marker of pre-eclampsia: a prospective case-control study. 9 38
20050765 2010
36
Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy. 9 38
20303587 2010
37
Effects of labor on placental expression of superoxide dismutases in preeclampsia. 9 38
20226522 2010
38
MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. 9 38
20452491 2010
39
Allelic variations in angiogenic pathway genes are associated with preeclampsia. 9 38
20223440 2010
40
Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. 9 38
20150910 2010
41
Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia - New perspectives to explain the pathophysiology. 9 38
20167365 2010
42
Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. 9 38
20002457 2010
43
VEGF in the muscular layer of placental blood vessels: immuno-expression in preeclampsia and intrauterine growth restriction and its association with the antioxidant status. 9 38
20184549 2010
44
Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy. 9 38
20070288 2010
45
Adipocytokines and endothelial function in preeclamptic women. 9 38
20075929 2010
46
Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. 9 38
20124108 2010
47
[Levels of immunoreactive cytokines in serum of women with preeclampsia or severe pregnancy hypertension]. 9 38
20486540 2010
48
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. 9 38
20101671 2010
49
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. 9 38
20074261 2010
50
Role of inflammatory cytokines and eNOS gene polymorphism in pathophysiology of pre-eclampsia. 9 38
20047583 2010

Variations for Pre-Eclampsia

ClinVar genetic disease variations for Pre-Eclampsia:

6 (show top 50) (show all 142)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NSD1 NM_022455.4(NSD1): c.6050G> A (p.Arg2017Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587784177 5:176710828-176710828 5:177283827-177283827
2 NOS3 NM_000603.5(NOS3): c.894T> G (p.Asp298Glu) single nucleotide variant Benign rs1799983 7:150696111-150696111 7:150999023-150999023
3 AGT NM_000029.4(AGT): c.803T> C (p.Met268Thr) single nucleotide variant Benign rs699 1:230845794-230845794 1:230710048-230710048
4 LOC108281140 ; MEGF6 duplication not provided 1:3411413-3431235 1:3494849-3514671
5 duplication not provided 1:41343608-41378076 1:40877936-40912404
6